Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Ambion Announce Co-Marketing Deal

NEW YORK, Aug 10 - Agilent Technologies and Ambion have agreed to co-market several of their products, including the Agilent 2100 bioanalyzer, Agilent RNA LabChip kits, and Ambion's RNA-related reagents. 

The companies said that by combining forces, they would be able to offer customers a range of products for improved RNA analysis.

"A key advantage of the LabChip technology for RNA analysis includes the ability to access the quality of an RNA sample," Bill Buffington, general manager of Agilent's life sciences division, said in a statement released Thursday. "Customers can use Ambion's RNase Zap to protect RNA from RNase degradation.”

Together Agilent of Palo Alto, Calif., and Ambion of Austin, Texas, will co-market the products and conduct market research. They did not disclose the financial terms of the deal.

Agilent’s RNA LabChip kits are developed and manufactured by Caliper Technology, Agilent's partner for its lab-on-a-chip business.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.